NVSNovartis PharmaceuticalsRunning, no new patients
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Prostatic Neoplasm
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 49 (final count)
- Started
- Jan 3, 2024
- Main results expected
- Dec 23, 2026
- Fully finished
- Dec 23, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PSA response
Measured over: From randomization until PSA nadir value of =< 0.2 ng/mL that is confirmed by a second (the next) PSA measurement >= 4 weeks later, up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05849298 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC